107 related articles for article (PubMed ID: 28013349)
1. Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1).
Saif MW; Heaton A; Lilischkis K; Garner J; Brown DM
Cancer Chemother Pharmacol; 2017 Feb; 79(2):303-314. PubMed ID: 28013349
[TBL] [Abstract][Full Text] [Related]
2. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo.
Alvero AB; Heaton A; Lima E; Pitruzzello M; Sumi N; Yang-Hartwich Y; Cardenas C; Steinmacher S; Silasi DA; Brown D; Mor G
Mol Cancer Ther; 2016 Jun; 15(6):1279-90. PubMed ID: 27196760
[TBL] [Abstract][Full Text] [Related]
3. Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results.
Coward JI; Barve MA; Kichenadasse G; Moore KN; Harnett PR; Berg D; Garner JS; Dizon DS
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206826
[TBL] [Abstract][Full Text] [Related]
4. Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells.
Kamsteeg M; Rutherford T; Sapi E; Hanczaruk B; Shahabi S; Flick M; Brown D; Mor G
Oncogene; 2003 May; 22(17):2611-20. PubMed ID: 12730675
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo.
Stevenson AJ; Ager EI; Proctor MA; Škalamera D; Heaton A; Brown D; Gabrielli BG
Sci Rep; 2018 Mar; 8(1):5144. PubMed ID: 29572477
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity.
Yee EMH; Brandl MB; Black DS; Vittorio O; Kumar N
Bioorg Med Chem Lett; 2017 Jun; 27(11):2454-2458. PubMed ID: 28408225
[TBL] [Abstract][Full Text] [Related]
7. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic flavonoids and new chromenes from Ficus formosana f. formosana.
Sheu YW; Chiang LC; Chen IS; Chen YC; Tsai IL
Planta Med; 2005 Dec; 71(12):1165-7. PubMed ID: 16395655
[TBL] [Abstract][Full Text] [Related]
10. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance.
Mirsalis JC; Schindler-Horvat J; Hill JR; Tomaszewski JE; Donohue SJ; Tyson CA
Cancer Chemother Pharmacol; 1999; 44(5):395-402. PubMed ID: 10501913
[TBL] [Abstract][Full Text] [Related]
11. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
12. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
13. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
14. The overexpression and nuclear translocation of Trx-1 during hypoxia confers on HepG2 cells resistance to DDP, and GL-V9 reverses the resistance by suppressing the Trx-1/Ref-1 axis.
Zhao L; Li W; Zhou Y; Zhang Y; Huang S; Xu X; Li Z; Guo Q
Free Radic Biol Med; 2015 May; 82():29-41. PubMed ID: 25656992
[TBL] [Abstract][Full Text] [Related]
15. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
[TBL] [Abstract][Full Text] [Related]
17. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
18. Tumoricidal activity of combining the agonistic DR5 antibody D-6 with cisplatin in C30 cisplatin-resistant ovarian cancer in vitro and in vivo.
Huang Y; Liang B; Jiang Q; Chen C; Yang K; Li C; Zheng A
Mol Med Rep; 2014 Jul; 10(1):183-90. PubMed ID: 24789319
[TBL] [Abstract][Full Text] [Related]
19. Toxicology and carcinogenesis studies of pyrogallol (CAS No. 87-66-1) in F344/N rats and B6C3F1/N mice (dermal studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2013 Feb; (574):1-167. PubMed ID: 23518671
[TBL] [Abstract][Full Text] [Related]
20. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Asselin E; Mills GB; Tsang BK
Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
